Coherus Queries Higher Dose Aflibercept Amid Biosimilar Eylea Deal

Potential For More Ophthalmology Products With ‘Additional Bandwidth’

 
• By Dean Rudge
  
question mark on a woman's hand. - Image
The anti-VEGF market is worth more than $7bn, Coherus says • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products